- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 213/71 - Atomes de soufre auxquels est lié un second hétéro-atome
Détention brevets de la classe C07D 213/71
Brevets de cette classe: 415
Historique des publications depuis 10 ans
|
45
|
36
|
38
|
40
|
33
|
16
|
34
|
19
|
18
|
9
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Sumitomo Chemical Company, Limited | 8996 |
20 |
| ImmunoGen, Inc. | 379 |
14 |
| Amgen Inc. | 4425 |
13 |
| Novartis AG | 10263 |
12 |
| Bristol-myers Squibb Company | 4729 |
9 |
| Syngenta Crop Protection AG | 6699 |
8 |
| Takeda Pharmaceutical Company Limited | 2715 |
8 |
| F. Hoffmann-La Roche AG | 7836 |
7 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 178 |
7 |
| Ube Industries, Ltd. | 770 |
7 |
| The University of Queensland | 661 |
7 |
| Oxford Drug Design Limited | 11 |
7 |
| Arcus Biosciences, Inc. | 164 |
6 |
| Inflazome Limited | 84 |
6 |
| Sanofi | 4293 |
5 |
| BASF SE | 21303 |
4 |
| Board of Regents, The University of Texas System | 6102 |
4 |
| The Johns Hopkins University | 5875 |
4 |
| Vertex Pharmaceuticals Incorporated | 1584 |
4 |
| Baylor College of Medicine | 1001 |
4 |
| Autres propriétaires | 259 |